PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Heitmeier, T.* ; Sydykov, A.* ; Lukas, C. ; Vroom, C.* ; Korfei, M.* ; Petrovic, A.* ; Klingel, K.* ; Günther, A.* ; Eickelberg, O. ; Weissmann, N.* ; Ghofrani, H.A.* ; Seeger, W.* ; Grimminger, F.* ; Schermuly, R.T.* ; Meiners, S. ; Kosanovic, D.*

Altered proteasome function in right ventricular hypertrophy.

Cardiovasc. Res. 116, 406-415 (2020)
Verlagsversion Postprint Forschungsdaten DOI PMC
Open Access Green
Aims: In patients with pulmonary hypertension, right ventricular hypertrophy (RVH) is a detrimental condition that ultimately results in right heart failure and death. The ubiquitin proteasome system has been identified as a major protein degradation system to regulate cardiac remodelling in the left heart. Its role in right heart hypertrophy, however, is still ambiguous.Methods and results: RVH was induced in mice by pulmonary artery banding (PAB). Both, expression and activity of the proteasome was found to be up-regulated in the hypertrophied right ventricle (RV) compared to healthy controls. Catalytic inhibition of the proteasome by the two proteasome inhibitors Bortezomib (BTZ) and ONX-0912 partially improved RVH both in preventive and therapeutic applications. Native gel analysis revealed that specifically the 26S proteasome complexes were activated in experimental RVH. Increased assembly of 26S proteasomes was accompanied by elevated expression of Rpn6, a rate-limiting subunit of 26S proteasome assembly, in hypertrophied cardiomyocytes of the right heart. Intriguingly, patients with RVH also showed increased expression of Rpn6 in hypertrophied cardiomyocytes of the RV as identified by immunohistochemical staining.Conclusion: Our data demonstrate that alterations in expression and activity of proteasomal subunits play a critical role in the development of RVH. Moreover, this study provides an improved understanding on the selective activation of the 26S proteasome in RVH that might be driven by the rate-limiting subunit Rpn6. In RVH, Rpn6 therefore represents a more specific target to interfere with proteasome function than the commonly used catalytic proteasome inhibitors.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
8.168
1.371
6
7
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Proteasome ; Proteasome Inhibition ; Rpn6 ; Pulmonary Artery Banding ; Right Ventricular Hypertrophy; Pulmonary Arterial-hypertension; Nf-kappa-b; Heart-failure; Bortezomib Treatment; In-vitro; Inhibition; Degradation; Carfilzomib; Dysfunction; Mechanisms
Sprache englisch
Veröffentlichungsjahr 2020
Prepublished im Jahr 2019
HGF-Berichtsjahr 2019
ISSN (print) / ISBN 0008-6363
e-ISSN 1755-3245
Zeitschrift Cardiovascular Research
Quellenangaben Band: 116, Heft: 2, Seiten: 406-415 Artikelnummer: , Supplement: ,
Verlag Oxford University Press
Verlagsort Great Clarendon St, Oxford Ox2 6dp, England
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Lung Health and Immunity (LHI)
POF Topic(s) 30202 - Environmental Health
Forschungsfeld(er) Lung Research
PSP-Element(e) G-501600-004
G-501600-001
DOI 10.1093/cvr/cvz103
WOS ID WOS:000515095600024
PubMed ID 31020333
Erfassungsdatum 2019-05-13
[➜Korrektur melden]